ENHANCING AND ENRICHING THERAPEUTIC OPTIONS IN PAEDIATRIC MEDICINE
A clinical stage pharmaceutical company focused on improving treatment options within rare paediatric diseases. Our lead project aims to establish a new era in neuroblastoma treatment.
Latest News
-
Essential Pharma acquires Renaissance Pharma Ltd and its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
April 9, 2024, UK | Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of….
-
Renaissance Pharma launches and announces the in-licensing of Hu14.18K322A (Hu14.18) from St.Jude Children's Hospital for the treatment of High-Risk Neuroblastoma
August 1, 2023, Manchester, UK | Renaissance Pharma Ltd., a rapidly emerging company focused on the development of life changing therapies in paediatric rare disease, today launches and announces the signing of an exclusive license agreement….